NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
16.97
+0.19 (1.13%)
At close: Jul 9, 2026, 4:00 PM EDT
16.99
+0.02 (0.12%)
After-hours: Jul 9, 2026, 5:11 PM EDT
NeuroPace Employees
NeuroPace had 220 employees as of March 31, 2026. The number of employees increased by 11 or 5.26% since the number was last reported on December 31, 2025.
Employees
220
Change
11
Growth
5.26%
Revenue / Employee
$452,409
Profits / Employee
-$98,023
Market Cap
578.57M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 220 | 11 | 5.26% |
| Dec 31, 2025 | 209 | 25 | 13.59% |
| Dec 31, 2024 | 184 | 13 | 7.60% |
| Dec 31, 2023 | 171 | 4 | 2.40% |
| Dec 31, 2022 | 167 | 1 | 0.60% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Orthofix Medical | 1,605 |
| Viemed Healthcare | 1,387 |
| Tactile Systems Technology | 1,086 |
| Cytek Biosciences | 678 |
| OrthoPediatrics | 602 |
| Pacific Biosciences of California | 485 |
| SS Innovations International | 483 |
| Cerus | 275 |
NPCE News
- 4 weeks ago - NeuroPace Transcript: AGM 2026 - Transcripts
- 5 weeks ago - NeuroPace announces FDA approval of ECoG Assistant - TheFly
- 5 weeks ago - NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting - Business Wire
- 5 weeks ago - NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care - Business Wire
- 7 weeks ago - NeuroPace price target raised to $20 from $19 at H.C. Wainwright - TheFly
- 2 months ago - NeuroPace reports Q1 EPS (20c), consensus (23c) - TheFly
- 2 months ago - NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M - TheFly
- 2 months ago - NeuroPace Earnings Call Transcript: Q1 2026 - Transcripts